Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Share Price Crosses Below 200 Day Moving Average - Time to Sell?

Novozymes A/S logo with Basic Materials background
Remove Ads

Shares of Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $60.97 and traded as low as $60.43. Novozymes A/S shares last traded at $60.69, with a volume of 7,859 shares changing hands.

Novozymes A/S Stock Performance

The company has a market cap of $27.26 billion, a price-to-earnings ratio of 36.84, a price-to-earnings-growth ratio of 3.87 and a beta of 0.91. The business has a 50-day simple moving average of $57.69 and a 200-day simple moving average of $60.88.

Novozymes A/S Increases Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Monday, April 7th will be given a $0.3758 dividend. The ex-dividend date is Monday, April 7th. This is a positive change from Novozymes A/S's previous dividend of $0.17. Novozymes A/S's dividend payout ratio (DPR) is currently 94.94%.

About Novozymes A/S

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Read More

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
Why Palantir’s Future Just Got a Massive Boost

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads